Johannes-Peter Stasch researcher
Stasch, Johannes-Peter 1954-
Stasch, Johannes-Peter
![Sudoc [ABES], France](/viaf/images/flags/SUDOC.png "Sudoc [ABES], France")
VIAF ID: 260981918 (Personal)
Permalink: http://viaf.org/viaf/260981918
Preferred Forms
-
100 0 _
‡a
Johannes-Peter Stasch
‡c
researcher
-
100 1 _
‡a
Stasch, Johannes-Peter
(sparse)
-
100 1 _
‡a
Stasch, Johannes-Peter
-
100 1 _ ‡a Stasch, Johannes-Peter
-
100 1 _ ‡a Stasch, Johannes-Peter
-
100 1 _
‡a
Stasch, Johannes-Peter
-
100 1 _ ‡a Stasch, Johannes-Peter ‡d (1954- ).
-
100 1 _
‡a
Stasch, Johannes-Peter
‡d
1954-
-
100 1 _
‡a
Stasch, Johannes-Peter
‡d
1954-
4xx's: Alternate Name Forms (2)
5xx's: Related Names (1)
Works
| Title | Sources |
|---|---|
| cGMP, c2009: |
|
| cGMP: generators, effectors and therapeutic implications / Harald H. H. W. Schmidt, Franz Hofmann, Johannes-Peter Stasch, editors. - Berlin ; Heidelberg, cop. 2009. |
|
| Discovery of the Soluble Guanylate Cyclase Stimulator Vericiguat (BAY 1021189) for the Treatment of Chronic Heart Failure |
|
| Early urinary and plasma biomarkers for experimental diabetic nephropathy. |
|
| Effects of stimulation of soluble guanylate cyclase on diabetic nephropathy in diabetic eNOS knockout mice on top of angiotensin II receptor blockade |
|
| Effects of the sGC stimulator BAY 41-2272 are not mediated by phosphodiesterase 5 inhibition |
|
| Elevated plasma human urotensin-II-like immunoreactivity in ischemic cardiomyopathy |
|
| Endothelin-1 overexpression restores diastolic function in eNOS knockout mice. |
|
| Evidence for two catalytic centers and Mn2+ as physiological cofactor of soluble guanylyl cyclase. |
|
| Fluorescence dequenching makes haem-free soluble guanylate cyclase detectable in living cells |
|
| Gender-dependent impact of risk factors for cardiovascular and non-cardiovascular mortality in end-stage renal disease patients on haemodialysis. |
|
| Identification of a soluble guanylate cyclase in RBCs: preserved activity in patients with coronary artery disease |
|
| Identification of acidic heterocycle-substituted 1H-pyrazolo[3,4-b]pyridines as soluble guanylate cyclase stimulators |
|
| Improvement of right heart structure and function by BAY 41-8543 in pulmonary artery banded mice. |
|
| Increased serum levels of tissue inhibitor of metalloproteinase-1 in patients with acute myocardial infarction. |
|
| Increases survival by apo-sGC activation via post-stroke blood brain barrier stabilisation and anti-inflammation. |
|
| Influence of cinaciguat on gastrointestinal motility in apo-sGC mice |
|
| Inhaled agonists of soluble guanylate cyclase induce selective pulmonary vasodilation |
|
| Inhibition of the TGFβ signalling pathway by cGMP and cGMP-dependent kinase I in renal fibrosis |
|
| Is kynurenine a novel and important vasodilator in human septic shock? |
|
| Kynurenine is an endothelium-derived relaxing factor produced during inflammation |
|
| Measuring oxidative burden and predicting pharmacological response in coronary artery disease patients with a novel direct activator of haem-free/oxidised sGC |
|
| New antithrombotics with an indazole structure |
|
| NO-insensitive sGCbeta1 H105F knockin mice: if NO has no place to go. |
|
| NO-unabhängige Aktivierung der löslichen Guanylatzyklase |
|
| Novel, selective indole-based ECE inhibitors: lead optimization via solid-phase and classical synthesis |
|
| Pharmacological actions of a novel NO-independent guanylyl cyclase stimulator, BAY 41-8543: in vitro studies |
|
| Pharmacological preconditioning with the guanylate cyclase activator cinaciguat (BAY 58-2667) protects against reperfusion injury after cardiopulmonary bypass |
|
| Pharmacotherapy of pulmonary hypertension |
|
| Phenotypes of sGC mutant mice in basic conditions, disease and shock |
|
| Pressure-independent effects of pharmacological stimulation of soluble guanylate cyclase on fibrosis in pressure-overloaded rat heart. |
|
| Pulmonary and systemic vasodilator responses to the soluble guanylyl cyclase activator, BAY 60-2770, are not dependent on endogenous nitric oxide or reduced heme |
|
| Raloxifene improves endothelial dysfunction in hypertension by reduced oxidative stress and enhanced nitric oxide production |
|
| Receptor binding assay for NO-independent activators of soluble guanylate cyclase |
|
| Relaxant effect of BAY 41-2272 and BAY 58-2667 in the gastrointestinal tract of apo-sGC mice. |
|
| Relaxin is an independent risk factor predicting death in male patients with end-stage kidney disease |
|
| Residues stabilizing the heme moiety of the nitric oxide sensor soluble guanylate cyclase |
|
| Riociguat reduces infarct size and post-infarct heart failure in mouse hearts: insights from MRI/PET imaging |
|
| Role of soluble guanylate cyclase in renal hemodynamics and autoregulation in the rat. |
|
| The selective Rho-kinase inhibitor azaindole-1 has long-lasting erectile activity in the rat. |
|
| sGC activators and stimulators attenuate ischemia/reperfusion injury of the lung. |
|
| sGC redox regulation and asthma. |
|
| Sila-Piperidine und silylierte Piperidine mit potentieller Antiparkinsonaktivität: Synthesen, Rezeptorbindungsstudien und Einflüsse auf die chemische Signalübertragung im zentralen Nervensystem |
|
| Singlet molecular oxygen regulates vascular tone and blood pressure in inflammation |
|
| The soluble guanylate cyclase activator BAY 58-2667 protects against morbidity and mortality in endotoxic shock by recoupling organ systems |
|
| Soluble guanylate cyclase agonists inhibit expression and procoagulant activity of tissue factor |
|
| Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease |
|
| Soluble guanylate cyclase stimulation prevents fibrotic tissue remodeling and improves survival in salt-sensitive Dahl rats |
|
| The soluble guanylate cyclase stimulator riociguat ameliorates pulmonary hypertension induced by hypoxia and SU5416 in rats. |
|
| The soluble guanylate cyclase stimulator riociguat and the soluble guanylate cyclase activator cinaciguat exert no direct effects on contractility and relaxation of cardiac myocytes from normal rats |
|
| The soluble guanylyl cyclase activator bay 58-2667 selectively limits cardiomyocyte hypertrophy |
|
| Stimulation of soluble guanylyl cyclase inhibits mesangial cell proliferation and matrix accumulation in experimental glomerulonephritis |
|
| Stimulation of soluble guanylyl cyclase protects against obesity by recruiting brown adipose tissue |
|
| Structural insights into sGC activation by different activators. |
|
| Structure/activity relationships of (M)ANT- and TNP-nucleotides for inhibition of rat soluble guanylyl cyclase α1β1. |
|
| Structure of cinaciguat (BAY 58-2667) bound to Nostoc H-NOX domain reveals insights into heme-mimetic activation of the soluble guanylyl cyclase |
|
| Targeting heme-oxidized soluble guanylate cyclase in experimental heart failure |
|
| Targeting the heme-oxidized nitric oxide receptor for selective vasodilatation of diseased blood vessels |
|
| Translational In Vivo Models for Cardiovascular Diseases |
|
| The uremic retention solute p-cresyl sulfate alters NO signal transduction by alteration of the soluble guanylate cyclase redox state |
|
| Urinary cGMP concentrations after exposure to radio-contrast media in patient at risk for contrast media induced nephropathy (CIN) predicts 90-day morbidity and mortality. |
|
| Urinary cGMP predicts major adverse renal events in patients with mild renal impairment and/or diabetes mellitus before exposure to contrast medium. |
|
| α1-A680T variant in GUCY1A3 as a candidate conferring protection from pulmonary hypertension among Kyrgyz highlanders |
|
